Regular check-ups and open communication between patients and healthcare professionals play a vital role in managing and mitigating any side effects that may arise during the course of semaglutide therapy
In small proof-of-concept phase 2 randomized controlled trials (RCTs) in patients with biopsy-confirmed MASH, liraglutide at 1.8 mg/day for 48 weeks (201), semaglutide at 0.4 mg/day for 72 weeks (202), and tirzepatide at 15 mg/week for 52 weeks (203) have been reported to achieve placebo-corrected percentages of participants meeting the criteria for resolution of MASH without worsening fibrosis by 30% (P = 0.019), 42% (P 10%) may lead to diabetes remission (237)
They are often prescribed to patients with type 2 diabetes who respond poorly to drugs such as metformin and sulfonylureas
Addressing these inequities is crucial to reducing the obesity burden
L-Carnitine shines in exercise performance and heart health, with studies suggesting it can reduce fatigue and improve cardiovascular markers
Compounded semaglutide can be safe when prescribed by a licensed provider and dispensed by an FDA-registered 503B compounding pharmacy that follows USP-797 sterile compounding standards